Invasive Candida species infections: a 5 year population-based assessment
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: Candida species have emerged as important causes of invasive infections and rates of resistance to standard antifungal therapies are rising. The objective of this study was to define the occurrence of, risk factors for, and antifungal susceptibilities of invasive Candida species infections in a large Canadian health region. METHODS: Population-based surveillance was conducted for invasive Candida species infections in the Calgary Health Region during a 5 year period and susceptibility testing was performed. RESULTS: The annual incidence of invasive Candida species infection was 2.9 per 100,000 population (0.2 and 2.8 per 100,000 for central nervous system and bloodstream infection, respectively). The very young and elderly were at highest risk for invasive Candida species infections. Several risk factors for developing invasive Candida species infection were identified with chronic haemodialysis, organ transplant recipient, and cancer patients at highest risk. Thirty percent (56/184; 43 susceptible, dose-dependent and 13 resistant) of isolates demonstrated reduced susceptibility to fluconazole. Only one (1%) isolate had reduced susceptibility to amphotericin B and six (3%) and three (2%) isolates had minimum inhibitory concentrations of >or=1 mg/L to voriconazole and caspofungin, respectively. Overall, 40% of patients died in-hospital for an annual mortality rate of 1.2 per 100,000. CONCLUSIONS: Candida species are an important cause of invasive infection and patients with co-morbidities and extremes of age are at highest risk. Alternatives to fluconazole should be considered for initial empiric therapy in patients with severe invasive Candida species infections.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Attributable Mortality of Nosocomial Candidemia, Revisited
Gudlaugsson, O., Gillespie, S., Lee, K., Berg, J. V., Hu, J., Messer, S., Herwaldt, L., Pfaller, M., & Diekema, D. (2003) · Clinical Infectious Diseases · doi:10.1086/378745 · Cited by 1,140
Denning, D. W. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14472-8 · Cited by 1,131
Walsh, T. J., Pappas, P., Winston, D. J., Lazarus, H. M., Petersen, F., Raffalli, J., Yanovich, S., Stiff, P., Greenberg, R., Donowitz, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejm200201243460403 · Cited by 979
Candidemia in a tertiary care hospital: epidemiology, risk factors, and predictors of mortality.
Fraser, V. J., Jones, M., Dunkel, J., Storfer, S., Medoff, G., & Dunagan, W. C. (1992) · Clinical Infectious Diseases · doi:10.1093/clind/15.3.414 · Cited by 679
Hajjeh, R. A., Sofair, A. N., Harrison, L. H., Lyon, G. M., Arthington-Skaggs, B. A., Mirza, S. A., Phelan, M., Morgan, J., Lee-Yang, W., Ciblak, M. A., et al. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.4.1519-1527.2004 · Cited by 649
Epidemiology of Candidemia in Swiss Tertiary Care Hospitals: Secular Trends, 1991–2000
Marchetti, O., Bille, J., Fluckiger, U., Eggimann, P., Ruef, C., Garbino, J., Calandra, T., Glauser, M., Tauber, M. G., Pittet, D., et al. (2004) · Clinical Infectious Diseases · doi:10.1086/380637 · Cited by 478 · cited 1×
“With increasing use of medical devices, immunosuppression, and broad spectrum antibacterials over recent decades, there has been a dramatic increase in invasive Candida species infections.(5,7,8) Concurrently, there have been rising rates of resistance to azoles, the current standard therapeutic agents for these infec…”
Kao, A. S., Brandt, M. E., Pruitt, W. R., Conn, L. A., Perkins, B. A., Stephens, D. S., Baughman, W. S., Reingold, A. L., Rothrock, G. A., Pfaller, M. A., et al. (1999) · Clinical Infectious Diseases · doi:10.1086/313450 · Cited by 457
Rees, J. R., Pinner, R. W., Hajjeh, R. A., Brandt, M. E., & Reingold, A. L. (1998) · Clinical Infectious Diseases · doi:10.1093/clinids/27.5.1138 · Cited by 397 · cited 2×
“The landmark population-based study conducted by Rees et al.(14) did not report antifungal susceptibilities testing results and the later work conducted by this group was limited by the fact that less than one-half of the isolates were tested for susceptibility to fluconazole, itraconazole and amphotericin B.”
Diekema, D. J., Messer, S. A., Brueggemann, A. B., Coffman, S. L., Doern, G. V., Herwaldt, L. A., & Pfaller, M. A. (2002) · Journal of Clinical Microbiology · doi:10.1128/jcm.40.4.1298-1302.2002 · Cited by 385 · cited 2×
“The lower incidence rate observed in our study was therefore not erroneously low as a result of limiting surveillance to hospital-based laboratories alone.(17,18) In contrast, one American study may have overestimated the true rate of candidaemia in their population by including non-residents of the surveillance area…”
Cited by
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174
Global and Multi-National Prevalence of Fungal Diseases-Estimate Precision
Bongomin, F., Gago, S., Oladele, R., & Denning, D. (2017) · Journal of Fungi · doi:10.3390/jof3040057 · Cited by 2,953
Church, D., Elsayed, S., Reid, O., Winston, B., & Lindsay, R. (2006) · Clinical Microbiology Reviews · doi:10.1128/cmr.19.2.403-434.2006 · Cited by 1,876
Self-citationEpidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Ellis, D., Tullio, V., Rodloff, A., Fu, W., & Ling, T. A. (2010) · Journal of Clinical Microbiology · doi:10.1128/jcm.02117-09 · Cited by 718
“glabrata to develop resistance to both triazoles (2, 10, 12, 17, 27, 46, 55, 63).”
BackgroundLeroy, O., Gangneux, J.-P., Montravers, P., Mira, J.-P., Gouin, F., Sollet, J.-P., Carlet, J., Reynes, J., Rosenheim, M., Regnier, B., et al. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e31819efac0 · Cited by 535
Population-Based Analysis of Invasive Fungal Infections, France, 2001–2010
Bitar, D., Lortholary, O., Le Strat, Y., Nicolau, J., Coignard, B., Tattevin, P., Che, D., & Dromer, F. (2014) · Emerging Infectious Diseases · doi:10.3201/eid2007.140087 · Cited by 426
Epidemiology of invasive candidiasis
Arendrup, M. C. (2010) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32833e84d2 · Cited by 376
Population-Based Epidemiology and Microbiology of Community-Onset Bloodstream Infections
Laupland, K. B., & Church, D. L. (2014) · Clinical Microbiology Reviews · doi:10.1128/cmr.00002-14 · Cited by 323
Self-citationLockhart, S. R., Iqbal, N., Cleveland, A. A., Farley, M. M., Harrison, L. H., Bolden, C. B., Baughman, W., Stein, B., Hollick, R., Park, B. J., et al. (2012) · Journal of Clinical Microbiology · doi:10.1128/jcm.01283-12 · Cited by 299
The global burden of fungal diseases
Vallabhaneni, S., Mody, R. K., Walker, T., & Chiller, T. (2016) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2015.10.004 · Cited by 292
Patients at High Risk of Invasive Fungal Infections: When and How to Treat
Rüping, M. J. G. T., Vehreschild, J. J., & Cornely, O. A. (2008) · Drugs · doi:10.2165/00003495-200868140-00002 · Cited by 253
Parkins, M. D., Sabuda, D. M., Elsayed, S., & Laupland, K. B. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm212 · Cited by 229
Self-citationEpidemiology of candidaemia and invasive candidiasis. A changing face
Quindós, G. (2014) · Revista Iberoamericana de Micología · doi:10.1016/j.riam.2013.10.001 · Cited by 219
Arendrup, M. C., Dzajic, E., Jensen, R. H., Johansen, H. K., Kjaldgaard, P., Knudsen, J. D., Kristensen, L., Leitz, C., Lemming, L. E., Nielsen, L., et al. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12212 · Cited by 206
One year prospective survey of Candida bloodstream infections in Scotland
Odds, F. C., Hanson, M. F., Davidson, A. D., Jacobsen, M. D., Wright, P., Whyte, J. A., Gow, N. A. R., & Jones, B. L. (2007) · Journal of Medical Microbiology · doi:10.1099/jmm.0.47239-0 · Cited by 176
Arendrup, M. C., Garcia-Effron, G., Lass-Flörl, C., Lopez, A. G., Rodriguez-Tudela, J.-L., Cuenca-Estrella, M., & Perlin, D. S. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01256-09 · Cited by 158
“They are among the preferred agents for invasive candidiasis, as a number of recent fungemia surveys have reported a considerable proportion of cases involving species with reduced susceptibility to fluconazole (3, 4, 24, 28, 31, 37, 44).”
BackgroundFever in the critically ill medical patient
Laupland, K. B. (2009) · Critical Care Medicine · doi:10.1097/ccm.0b013e3181aa6117 · Cited by 139
“Patients who are colonized and who have prolonged admission, underlying medical comorbid illnesses, and invasive catheters and who are recipients of parenteral nutrition, hemodialysis, immunosuppressive therapy, and broad-spectrum antibacterials are at increased risk (20, 21).”
BackgroundSelf-citationAstvad, K. M. T., Johansen, H. K., Røder, B. L., Rosenvinge, F. S., Knudsen, J. D., Lemming, L., Schønheyder, H. C., Hare, R. K., Kristensen, L., Nielsen, L., et al. (2018) · Journal of Clinical Microbiology · doi:10.1128/jcm.01564-17 · Cited by 125
Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Barton, R., Bijie, H., Bille, J., Chang, S.-C., da Luz Martins, M., Duse, A., et al. (2010) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2010.01.002 · Cited by 80
“glabrata as a cause of IC and its associated resistance profile may be influenced not only by exposure to azoles, but also by patient age, underlying disease, and geographic location (Alexander et al., 2005; Arendrup et al., 2008; Chow et al., 2008; Hachem et al., 2008; Klevay et al., 2009; Laupland et al., 2005; Lee…”
BackgroundArendrup, M. C., Rodriguez-Tudela, J.-L., Park, S., Garcia-Effron, G., Delmas, G., Cuenca-Estrella, M., Gomez-Lopez, A., & Perlin, D. S. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01364-10 · Cited by 57
Susceptibility patterns of Candida species recovered from Canadian intensive care units
Laverdiere, M., Labbé, A.-C., Restieri, C., Rotstein, C., Heyland, D., Madger, S., & Stewart, T. (2007) · Journal of Critical Care · doi:10.1016/j.jcrc.2006.10.038 · Cited by 42
Prophylaxis, empirical and preemptive treatment of invasive candidiasis
Playford, E. G., Lipman, J., & Sorrell, T. C. (2010) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e32833e10e8 · Cited by 41
Kuhn, D. M., & Vyas, V. K. (2012) · FEMS Yeast Research · doi:10.1111/j.1567-1364.2011.00785.x · Cited by 38
“, 1991), and the attributable mortality of patients with candidemia still approaches 40% (Laupland et al., 2005).”
Background
Metadata
- Authors
- Laupland, K. B., Gregson, D. B., Church, D. L., Ross, T., & Elsayed, S.
- Venue
- Journal of Antimicrobial Chemotherapy
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-07-22
- Volume
- 56
- Issue
- 3
- Pages
- 532-537
- ISSN
- 0305-7453 (ISSN-L)
- 1460-2091
- OpenAlex
- W2143443625
- Cited by
- 130
- References
- 12
- FWCI
- 5.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.